Global Antiprotozoal Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Antiprotozoal Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Antiprotozoal agents (ATC codeATC P01) is a class of pharmaceuticals used in treatment of protozoan infection.
Antiprotozoal Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antiprotozoal Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
Antiprotozoals are used to treat protozoal infections, which include amebiasis, giardiasis, cryptosporidiosis, microsporidiosis, malaria, babesiosis, trypanosomiasis, Chagas disease, leishmaniasis, and toxoplasmosis.[5] Currently, many of the treatments for these infections are limited by their toxicity. Some antiprotozoal drugs include the antimalarials Aralen (chloroquine), Daraprim (pyrimethamine), Lariam (mefloquine) and Plaquenil (hydroxychloroquine); Flagyl (metronidazole) which is active against Entamoeba histolytica and Trichomonas vaginalis; and Mepron (atovaquone) for Pneumocystis carinii.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antiprotozoal Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Sanofi
Akthelia Pharmaceuticals Ltd
GlaxoSmithKline Plc
Immuron Ltd
Microbiotix Inc
Protein Potential LLC
Dr. Reddy’s Laboratories
Mission Pharmacal
Aceto Corp.
Mylan Pharmaceuticals
Impax Laboratories
Pfizer
Lupin Pharmaceuticals
Glenmark Pharmaceuticals
Sun Pharmaceutical
Heritage Pharmaceuticals
Gilead Sciences
Johnson & Johnson
Bristol-Myers Squibb
Profounda
Knight Therapeutics
Albert David
Wanlong
Fangsheng
KPC Pharmaceuticals
Guilin Pharmaceuticals
Pude Pharmaceutica
Segment by Type
by Diseases
Amoebic Dysentery
Antimalarial Drug
Leishmaniasis & Chagas Disease
by Drugs
Metronidazole
Atovaquone
Benznidazole
Dehydroemetine
Eflornithine
Emetine
Fenbendazole
Iodoquinol
Melarsoprol
Others (like Meglumine antimonite, Nifurtimox, Pentamidine, etc.)
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antiprotozoal Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Antiprotozoal Drugs introduction, etc. Antiprotozoal Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Antiprotozoal Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Antiprotozoal Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antiprotozoal Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
Antiprotozoals are used to treat protozoal infections, which include amebiasis, giardiasis, cryptosporidiosis, microsporidiosis, malaria, babesiosis, trypanosomiasis, Chagas disease, leishmaniasis, and toxoplasmosis.[5] Currently, many of the treatments for these infections are limited by their toxicity. Some antiprotozoal drugs include the antimalarials Aralen (chloroquine), Daraprim (pyrimethamine), Lariam (mefloquine) and Plaquenil (hydroxychloroquine); Flagyl (metronidazole) which is active against Entamoeba histolytica and Trichomonas vaginalis; and Mepron (atovaquone) for Pneumocystis carinii.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antiprotozoal Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Sanofi
Akthelia Pharmaceuticals Ltd
GlaxoSmithKline Plc
Immuron Ltd
Microbiotix Inc
Protein Potential LLC
Dr. Reddy’s Laboratories
Mission Pharmacal
Aceto Corp.
Mylan Pharmaceuticals
Impax Laboratories
Pfizer
Lupin Pharmaceuticals
Glenmark Pharmaceuticals
Sun Pharmaceutical
Heritage Pharmaceuticals
Gilead Sciences
Johnson & Johnson
Bristol-Myers Squibb
Profounda
Knight Therapeutics
Albert David
Wanlong
Fangsheng
KPC Pharmaceuticals
Guilin Pharmaceuticals
Pude Pharmaceutica
Segment by Type
by Diseases
Amoebic Dysentery
Antimalarial Drug
Leishmaniasis & Chagas Disease
by Drugs
Metronidazole
Atovaquone
Benznidazole
Dehydroemetine
Eflornithine
Emetine
Fenbendazole
Iodoquinol
Melarsoprol
Others (like Meglumine antimonite, Nifurtimox, Pentamidine, etc.)
Segment by Application
Hospital
Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antiprotozoal Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Antiprotozoal Drugs introduction, etc. Antiprotozoal Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Antiprotozoal Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices